ASTROCYTOMA, IDH-MUTANT, GRADE 2
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 2 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 2 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New brain cancer combo seeks safe dose in early trial
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of an experimental drug called triapine when given with radiation therapy. It's for adults whose glioblastoma or astrocytoma brain tumors have returned after previous treatment. The main goal is to find out if the combina…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 21:25 UTC
-
New pill targets genetic flaw in aggressive brain cancers
Disease control Recruiting nowThis study is testing an oral drug called safusidenib for adults with specific types of brain tumors that have a genetic change called an IDH1 mutation. The main goal is to see if the drug can safely control the tumor and delay its growth or return after standard treatments. The …
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC